Improving skin quality and self-esteem in breast cancer survivors on hormone therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the effects of aromatase inhibitor therapy on skin quality and self-esteem in breast cancer survivors. Participants will undergo skin assessments using advanced imaging technology and complete surveys to report their self-esteem and quality of life. Additionally, they will receive consultations with an aesthetician to explore skincare interventions. The study aims to measure both objective skin quality changes and subjective improvements in patients' self-reported well-being.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \* Female ≥ 18 years

  * Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion
  * Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and/or progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2)
  * Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included
  * Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period
  * Willing and able to provide consent

Exclusion Criteria:

* \* Patients who have previously taken AIs

  * Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent

Where it's running

• Mayo Clinic in Florida
  Jacksonville, Florida, United States Recruiting

Study contacts

• Principal investigator: Leila M. Tolaymat, M.D. — Mayo Clinic
• Study coordinator: Clinical Trials Referral Office
• Email: mayocliniccancerstudies@mayo.edu
• Phone: 855-776-0015

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Navigation program to boost survivorship support participation for non-metastatic breast cancer survivors

  This program tests whether a patient navigation service helps non-metastatic breast cancer survivors use survivorship support services more often.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07699991

• Resistant potato starch to reduce joint and muscle symptoms in people starting aromatase inhibitors for early-stage or high-risk breast cancer

  This phase II trial will test whether taking resistant potato starch can reduce joint pain and stiffness in people with stage 0–III or high-risk breast cancer who are starting aromatase inhibitor therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07443943

• 5-strain probiotic to prevent bone loss during aromatase inhibitor therapy

  This trial will try a 5-strain probiotic called WBF-038 to see if it prevents bone loss in people with early-stage hormone receptor–positive breast cancer who are starting aromatase inhibitor therapy.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT07044310

• Blended e-Health Program to Help Women with Breast or Gynecologic Cancer Manage Fear of Cancer Progression

  This trial tests a blended online and group program to see if it helps women with breast or gynecologic cancer feel less fear that their cancer could grow or spread.

  Recruiting at 11 sites City of Hope Medical Center · Arcadia, California and 10 other locations · NCT07741968

• Personalized Exercise Plan for Breast Cancer Survivors on Chemotherapy

  This trial tests whether adding a guided exercise program to a healthy-lifestyle education plan helps breast cancer patients undergoing chemotherapy maintain fitness, heart health, and quality of life.

  Recruiting at 3 sites Wake Forest University Health Sciences · Winston-Salem, North Carolina and 3 other locations · NCT07474090

• Goserelin Injections: Is Upper-Gluteal Dosing as Good as Abdominal Dosing for OFS in Localized and Locally Advanced HR+ Breast Cancer

  This phase 2 trial tests whether giving goserelin acetate injections in the upper gluteal region works as well as abdominal injections for suppressing ovarian function in premenopausal women with localized or locally advanced hormone receptor–positive breast cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07460752

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.